Table 2.
Results of RFA in 22 patients with long-term follow-up.
| Total sessions of RFA | 26 |
| One session/ Two sessions | 18/4 |
| Average sessions | 1.20.4 |
| Ablative time (min, range) | 21.3±13.7 (3-48) |
| F/U1 duration (mo, range) | 28.8±9.0 (15-45) |
| Roll-off (+/-) | 21/1 |
| Complications | |
| Local pain | 11 |
| Nausea/vomiting | 4 |
| Fever | 1 |
| Local-free interval (M2, range) | 22.2±10.0 (4-45) |
| Tumor-free interval (M2, range) | 18.5±11.4 (2-45) |
| Local recurrence rate | |
| 12M/24M/30M | 13.6% / 33.3% /46.6% |
| Overall recurrence rate | |
| 12M/24M/30M | 36.4%/56.2%/56.2% |
| Survival interval (M2, range) | 28.7±9.1 (15-45) |
| Pre-RFA / Post-RFA3 | |
| Albumin (g/dL) | 3.8±0.5/4.20.6 |
| GOT (U/L) | 63.5±32.9/70.434.2 |
| GPT (U/L) | 71.1±40.0/79.234.2 |
| T. Bili.4 (mg/dL) | 1.1±0.5/1.00.5 |
| Alk-P5 (U/L) | 116.0±46.3/123.546.1 |
| AFP6 level (ng/mL) | |
| Pre-treatment (range) | 223.5±663.1 (3-2870) |
| Post-treatment | 41.3±90.6 (3-422) |
| Decrease AFP > 50% post RFA | |
| Yes / No | 8/14 |
1
F/U: Follow-up
2
M: months
3
Data of pre-RFA / Data of post-RFA
4
T. Bili: total bilirubin level
5
Alk-P: alkaline phosphatase level
6
AFP: alpha-fetoprotein.